Bronchitis, Chronic, Pulmonary Disease, Chronic Obstructive
Conditions
Keywords
COPD, Chronic bronchitis, Chronic obstructive pulmonary disease, Shortness of breath, Dyspnea, Bronchitis
Brief summary
To determine if ABX-IL8 will improve shortness of breath.
Detailed description
Chronic Obstructive Pulmonary Disease (COPD) is defined as a disease state characterized by the presence of airflow obstruction due to chronic bronchitis or emphysema. The airflow obstruction is generally progressive, may be accompanied by airway hyper-reactivity, and may be partially reversible. Inflammation in the lungs is triggered by exposure to inhaled toxic substances that can lead to tissue damage, mucous secretion, airways narrowing and tissue destruction. Interleukin-8 (IL-8) plays a major role in elevating sputum in patients with COPD and may contribute to tissue destruction. Therefore, the highly specific antibody to IL-8 (such as ABX-IL8) may help to reduce mucous production and tissue destruction.
Interventions
DRUGABX-IL8
Sponsors
Abgenix
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* \> 50 years old * \> 20 pack-year of smoking * Diagnosed with COPD and chronic bronchitis
Exclusion criteria
* Patients with bronchiectasis, cystic fibrosis, tuberculosis, asthma, alpha-1 antitrypsin deficiency, CHF * Require oxygen therapy * Uncontrolled hypertension * HIV or Hepatitis * Recent history of COPD exacerbation * Patients with cancer * Recent history of infection
Countries
United States
Outcome results
None listed